(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Pharmaceutical stocks declined as President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr. to run the Department ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including World <a target=_blank ...

The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...

Donald Trump's nomination of Robert F Kennedy Jr. to lead the Department of Health and Human Services sent shares of major ...

Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...

Robert F. Kennedy has espoused a number of unorthodox views on public health, most notably questioning the safety and ...

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax (NVAX – Research Report) today and set a price target of ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Novavax received clearance from the FDA to move forward with phase 3 clinical trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical hold that ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...